Joint Statistical Meetings 2018

Slides:



Advertisements
Similar presentations
Introduction to molecular dating methods. Principles Ultrametricity: All descendants of any node are equidistant from that node For extant species, branches,
Advertisements

Study Size Planning for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
CHAPTER 21 Inferential Statistical Analysis. Understanding probability The idea of probability is central to inferential statistics. It means the chance.
HSRP 734: Advanced Statistical Methods July 24, 2008.
Estimation and Reporting of Heterogeneity of Treatment Effects in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare.
Elements of a clinical trial research protocol
Journal Club Alcohol and Health: Current Evidence March-April 2007.
How does the process work? Submissions in 2007 (n=13,043) Perspectives.
The AutoSimOA Project Katy Hoad, Stewart Robinson, Ruth Davies Warwick Business School WSC 07 A 3 year, EPSRC funded project in collaboration with SIMUL8.
The AutoSimOA Project Katy Hoad, Stewart Robinson, Ruth Davies Warwick Business School OR49 Sept 07 A 3 year, EPSRC funded project in collaboration with.
CHAPTER 6 Statistical Analysis of Experimental Data
Forecasting McGraw-Hill/Irwin Copyright © 2012 by The McGraw-Hill Companies, Inc. All rights reserved.
AGEC 622 Mission is prepare you for a job in business Have you ever made a price forecast? How much confidence did you place on your forecast? Was it correct?
Other Univariate Statistical Process Monitoring and Control Techniques
RANDOMIZED CLINICAL TRIALS. What is a randomized clinical trial?  Scientific investigations: examine and evaluate the safety and efficacy of new drugs.
Survival Analysis A Brief Introduction Survival Function, Hazard Function In many medical studies, the primary endpoint is time until an event.
Making all research results publically available: the cry of systematic reviewers.
Forecasting and Statistical Process Control MBA Statistics COURSE #5.
Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor.
CI - 1 Cure Rate Models and Adjuvant Trial Design for ECOG Melanoma Studies in the Past, Present, and Future Joseph Ibrahim, PhD Harvard School of Public.
Introduction to Control Charts: XmR Chart
2005 CLRS September 2005 Boston, Massachusetts
 Is there a comparison? ◦ Are the groups really comparable?  Are the differences being reported real? ◦ Are they worth reporting? ◦ How much confidence.
Optimal cost-effective Go-No Go decisions Cong Chen*, Ph.D. Robert A. Beckman, M.D. *Director, Merck & Co., Inc. EFSPI, Basel, June 2010.
Lecture 20: Study Design and Sample Size Estimation in TTE Studies.
Introduction to Survival Analysis Utah State University January 28, 2008 Bill Welbourn.
INTERNAL ACHIEVEMENT STANDARD 3 CREDITS Time Series 1.
Pro gradu –thesis Tuija Hevonkorpi.  Basic of survival analysis  Weibull model  Frailty models  Accelerated failure time model  Case study.
August 20, 2003FDA Antiviral Drugs Advisory Committee Meeting 1 Statistical Considerations for Topical Microbicide Phase 2 and 3 Trial Designs: A Regulatory.
1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.
Simulation Study for Longitudinal Data with Nonignorable Missing Data Rong Liu, PhD Candidate Dr. Ramakrishnan, Advisor Department of Biostatistics Virginia.
1 BLA Sipuleucel-T (APC-8015) FDA Statistical Review and Findings Bo-Guang Zhen, PhD Statistical Reviewer, OBE, CBER March 29, 2007 Cellular, Tissue.
Risk Assessment: Questions to the Committee 1.What estimate(s) should be used to reflect the prevalence of vCJD in the U.K.? Proposal: We propose using.
Course: Research in Biomedicine and Health III Seminar 5: Critical assessment of evidence.
Statistical NLP: Lecture 4 Mathematical Foundations I: Probability Theory (Ch2)
Circulatory System Devices Panel Questions for Discussion EMBOL·X Aortic Filter October 23, 2002.
1 Chapter 6 SAMPLE SIZE ISSUES Ref: Lachin, Controlled Clinical Trials 2:93-113, 1981.
Zometa for Prostate Cancer Bone Metastases Protocol 039 Amna Ibrahim, M.D. Oncology Drug Products FDA.
Response, PFS or OS – what is the best endpoint in advanced colorectal cancer? Marc Buyse IDDI, Louvain-la-Neuve & Hasselt University
Methods and Statistical analysis. A brief presentation. Markos Kashiouris, M.D.
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
BINARY LOGISTIC REGRESSION
Brady Et Al., "sequential compression device compliance in postoperative obstetrics and gynecology patients", obstetrics and gynecology, vol. 125, no.
Logistic Regression APKC – STATS AFAC (2016).
The Importance of Adequately Powered Studies
Forecasting Methods Dr. T. T. Kachwala.
FDA’s IDE Decisions and Communications
Perez EA et al. SABCS 2009;Abstract 80.
Interventional trials
5. BRIDGING THE GAP between Pharmacometricians and Biostatisticians
Chapter 8: Inference for Proportions
Strategies for Implementing Flexible Clinical Trials Jerald S. Schindler, Dr.P.H. Cytel Pharmaceutical Research Services 2006 FDA/Industry Statistics Workshop.
Shuangge Ma, Michael R. Kosorok, Thomas D. Cook
Mark Rothmann U.S. Food and Drug Administration September 14, 2018
Aiying Chen, Scott Patterson, Fabrice Bailleux and Ehab Bassily
Common Problems in Writing Statistical Plan of Clinical Trial Protocol
Joanna Romaniuk Quanticate, Warsaw, Poland
Statistical NLP: Lecture 4
EVENT PROJECTION Minzhao Liu, 2018
Volume 375, Issue 9719, Pages (March 2010)
BEC 30325: MANAGERIAL ECONOMICS
THE LANCET Oncology Volume 19, No. 1, p27–39, January 2018
Use of Piecewise Weighted Log-Rank Test for Trials with Delayed Effect
Design and Analysis of Survival Trials with Treatment Crossover, delayed treatment effect and treatment dilution Presenter: Xiaodong Luo– R&D-SANOFI US.
MGS 3100 Business Analysis Regression Feb 18, 2016
Björn Bornkamp, Georgina Bermann
Gregory Levin, FDA/CDER/OTS/OB/DBIII
How Should We Select and Define Trial Estimands
Oncology Biostatistics
Presentation transcript:

Joint Statistical Meetings 2018 Real-time Study Milestone Projection in Clinical Trials with Time-to-Event Endpoints Yanping Liu, Gang Jia Joint Statistical Meetings 2018

Introduction In randomized clinical trials with time-to-event endpoints, there are commonly one or more planned interim analyses plus a final analysis, spanning over a few years. Predicting the timing of these analyses (i.e predicting the number of events within a certain timeframe) is critical for success: Resource allocation; Regulatory submission planning; Clinical operation; Business strategy. … In practice, the protocol pre-specified triggers (i.e. # of events) are often ‘hit or miss’. The essence of such prediction mainly depends on patient accrual and event rates, which might vary throughout the whole trial.

Short-term Projection Prediction Methods Short-term Projection Linear Extrapolation Average Rate Method Long-term Projection Exposure-adjusted Event Rate Parametric Estimation Piecewise Constant Risk Approach

Short-term Projection Linear Extrapolation Plot cumulative # of events over time and extrapolate the near future values Average Rate Method Average over the preceding 3/6 monthly events Easy to implement Good for short-term projection Assumption of the same rate or same average rate before and after the projection

Long-term Projection Exposure-adjusted Event Rate Pros: relatively easy to implement Cons: keep the original assumptions and model Parametric Estimation Pros: relatively precise; utilize all observed data Cons: more complicated; if assumption misses, then not accurate; model selection is important Piecewise Constant Risk Approach Survival function is not smooth A sequential testing approach, using likelihood ratio statistics A sequence of significance levels, which adequately control the overall significance level.

Summary We should choose different methods based on different predicting timing and different practical data. Monitoring the data pattern during the study is important. If change points exist, the piecewise constant risk approach would be more appropriate.